Pomona, NY (PRWEB) May 02, 2013
Invado Pharmaceuticals announced that Jean Hamker, RN of the Cleveland Clinic Taussig Cancer Institute presented data from a NeutraSal study at last week's ONS World Congress. Hamker's poster presentation was a comparison of NeutraSal treatment versus salt and soda in the prevention and reduction of oral mucositis in head and neck patients undergoing radiation and/or chemotherapy. Of the 35 patients that were evaluated, it was found that oral toxicities associated with treatment were significantly lower with NeutraSal than historical averages when patients utilized salt and soda. NeutraSal patients reported lower rates of oral mucositis, xerostomia, oral pain and less opiod use.